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Abstract
Background: Viruses that are incorporating host cell proteins might trigger autoimmune diseases.
It is therefore of interest to identify possible host proteins associated with viruses, especially for
enveloped viruses that have been suggested to play a role in autoimmune diseases, like human
herpesvirus 6A (HHV-6A) in multiple sclerosis (MS).
Results: We have established a method for rapid and morphology preserving purification of HHV-
6A virions, which in combination with parallel analyses with background control material released
from mock-infected cells facilitates qualitative and quantitative investigations of the protein content
of HHV-6A virions. In our iodixanol gradient purified preparation, we detected high levels of viral
DNA by real-time PCR and viral proteins by metabolic labelling, silver staining and western blots.
In contrast, the background level of cellular contamination was low in the purified samples as
demonstrated by the silver staining and metabolic labelling analyses. Western blot analyses showed
that the cellular complement protein CD46, the receptor for HHV-6A, is associated with the
purified and infectious virions. Also, the cellular proteins clathrin, ezrin and Tsg101 are associated
with intact HHV-6A virions.
Conclusion:  Cellular proteins are associated with HHV-6A virions. The relevance of the
association in disease and especially in autoimmunity will be further investigated.
Background
Human herpesvirus 6A and 6B (HHV-6A and 6B) are
members of the betaherpesvirus subfamily. HHV-6B is a
ubiquitous virus and causes the common childhood dis-
ease exanthem subitum [1], whereas the seroprevalence
rate and pathological features for HHV-6A is unknown.
Both variants are neurotropic and can cause neurological
disorder [2-6] and might be potential pathologic agents in
multiple sclerosis (MS), though the mechanism(s) is not
understood [7]. Putatively, incorporation of host proteins
into herpes virions could have implications for autoim-
munity as indicated by studies of human cytomegalovirus
(HCMV) [8,9]. Several reports demonstrate that host pro-
teins are incorporated into enveloped viral particles [10-
13]. However, the purity of the virus preparations and if
host proteins are truly incorporated have been debated
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since cellular vesicles might contaminate the viral prepa-
rations during purification by sedimentation in sucrose
gradients [14,15]. The drawbacks with sucrose gradients
have been overcome by a switch to iodixanol gradients
[16-18].
We have set up a purification protocol, including iodixa-
nol gradient, for HHV-6A that result in carefully purified,
intact and infectious viral particles. To control for cellular
contaminants, the background produced by mock-
infected cells was determined for every step in the purifi-
cation scheme and during the characterisation of the
HHV-6A virions. The cellular proteins CD46, clathrin,
ezrin and Tsg101 were found to be associated with the
purified HHV-6A virions. Actin was also, to a lower extent,
found in the purified HHV-6A virion samples.
Results
HHV-6A production
During purification and characterisation of virions, a
major obstacle is contaminations of the viral prepara-
tions. The contaminations can stem from soluble proteins
derived from the producer cells or from serum in the cul-
ture medium. An additional source is cellular proteins in
released and co-purified cellular vesicles. To decrease the
contaminations we optimised the production and collec-
tion of HHV-6A. Our first concern was the presence of
high concentration of serum in the culture medium. Rou-
tinely, 10% serum was used for propagation of HHV-6A
[19]. We tested whether infections could be performed
with only 2% serum present. However, this led to 2 log
reduction of viral DNA copies in medium as determined
by real-time PCR (data not shown). We then changed
from 10% serum at 24 h post infection to 2% serum and
found that the viral DNA copy number in medium
remained equivalent to infections grown in 10% serum.
Our second concern was that release of contaminating
material from the producer cells would increase with
time. Therefore, the growth characteristics of HHV-6A
were investigated and ideal time point for collection of
viral particles as early as possible after infection was deter-
mined. Infections of JJHAN caused an increase of viral
DNA copies in cells and medium over time (Fig. 1A). After
3 days, the viral DNA copy number in the medium was
about 1.4 × 107 per ml (= 7.1 log10) and further produc-
tion gave only an insignificant increase as measured by
real-time PCR analyses (Fig. 1A). This meant that at 3 days
post infection (dpi), the infected cells had released 279 ±
103 viral DNA copies/infected cell (n = 3). The release of
virion DNA corresponded well with the accumulation of
intracellular viral DNA, which also increased rapidly to 3
dpi (Fig. 1A). Cells infected with HHV-6A displayed cyto-
pathic effects (CPE) as enlargement of cells at day 3 (Fig.
1B), in comparison to mock-infected cells (Fig. 1C) as
shown by light microscopic analyses. Altogether, we
decided to perform infections in 10% serum and collect
HHV-6A in 2% serum media from 1 dpi to 3 dpi. A third
concern was whether the majority of cells in culture were
infected with HHV-6A and thereby contributing to effi-
cient release of virions. Immunofluorescence analysis
showed that approximately 80% of the infected cells were
stained by the HHV-6 specific monoclonal antibody
gp60/110 at day 3 (Fig. 1D). A low number of mock-
infected cells showed a diffuse red staining, but were neg-
ative for nuclear staining by DAPI and therefore most
likely had non-specifically taken up rhodamine (Fig. 1E).
We concluded that most cells were infected and contrib-
uted to HHV-6A production.
Purification of HHV-6A particles
Media was collected from HHV-6A-infected cells and
mock-infected control cells from 1 to 3 dpi. Importantly,
the mock control was included in order to estimate the
background level of contaminations during purification
and analyses of HHV-6A particles. The virus and mock
sample were purified in several steps as detailed in mate-
rial and methods. Briefly, the collection media were clari-
fied by short centrifugations, concentrated by ultra
filtration and filtered through a 0.45 µm filter. The viral
particles, and mock material, were finally purified by sed-
imentation on a 5–25% w/v iodixanol gradient. The
iodixanol gradient fractions were concentrated into pel-
lets by centrifugation and analyzed by SDS-PAGE fol-
lowed by silver staining. As seen in lanes 1 and 2 in Fig. 2A
and 2B, a considerable amount of protein containing
material from both HHV-6A and mock preparations was
detected in the top fractions of the iodixanol gradient
while the bottom fractions contained much less proteins.
A large difference in protein pattern between HHV-6A and
mock samples is seen in fractions 11–15 (Fig 2A and 2B,
lane 4). A number of clearly concentrated probable viral
proteins are displayed in the HHV-6A sample while the
mock shows a diffuse background. The presence of HHV-
6A in fractions 11–15 was confirmed by parallel western
blot analyses using the monoclonal HHV-6 antibody
gp60/110 (Fig. 2A, lower). A strong signal for viral protein
gp60 and a weak signal for gp110 were detected in these
fractions. As expected, gp60/110 was not detected in the
parallel mock analyses (Fig. 2B, lower). The faint bands
detected in the top fractions of the mock sample gradient
were most likely the result of unspecific reactions between
the antibodies and serum proteins or cellular proteins (Fig
2B, lower, lanes 1 and 2). Corresponding bands were also
seen in the HHV-6A blot (Fig. 2A, lower, lanes 1 and 2).
Furthermore, real-time PCR analyses of viral DNA in the
gradient fractions revealed a peak of HHV-6A DNA in frac-
tions 11–15 as shown in Fig. 2C. The density of these frac-
tions was determined to be between 1.09–1.12 g/ml.
Although the majority of the initial mock material was
removed during the purification procedure, a backgroundVirology Journal 2007, 4:101 http://www.virologyj.com/content/4/1/101
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was still present in the gradient fractions 11–15 (Fig. 2B,
lane 4). We hypothesized that the background repre-
sented mostly proteins from the serum in the culture
medium rather than contaminating host proteins. As a
control for solely medium proteins an equal volume of
fresh culture media was also concentrated, filtered and
sedimented in iodixanol gradient and fractions 11–15
were analyzed in parallel with HHV-6A and mock prepa-
rations (Fig. 2D). The medium control clearly shows that
the background in purified mock corresponded to culture
media proteins. This background was increased if the vir-
ions were harvested in culture media containing 10%
serum (data not shown). We concluded that the purifica-
tion of HHV-6A virions removed a substantial amount of
cellular contaminating material, but that the virions were
still to some extent contaminated with soluble serum pro-
teins.
Purification of HHV-6A relative to cellular material
Infected cells and parallel mock cultures were metaboli-
cally labelled during a few hours with 35S-methionine to
label synthesizing cellular and viral proteins. By this
approach the purification can be followed relative to cel-
lular material, disregarding the non-labelled serum con-
tamination. However, the JJHAN cells were sensitive to
the toxic effects of the isotope, which was manifested as
an increase in background material over time. Hence, the
labelling period was minimized to only four hours and
thereafter virus particles were collected for four hours
without additional labelling. Two time points for label-
ling and collection of particles after infection were chosen.
The first time point was at 1 dpi when viral DNA is
detected in the producer cells, but yet no viral particles are
released into the media (Fig. 1A). Thus, labelled proteins
present in media at 1 dpi should represent the back-
ground level of cellular proteins released from both
infected and mock-infected cells. The second time point
was at 3 dpi when the production level of virions was high
(Fig. 1A). To enable quantitative comparisons of the
amount of proteins in HHV-6A and mock preparations,
the samples were equalized based on the number of living
cells in the cultures at the end of collection. This is crucial
as the mock-infected cells, but not HHV-6A-infected cells,
divided during the collection period and hence would
have given an overestimation of released cellular material.
In Fig. 3, the protein patterns of purified material from
infected and mock cells, isolated from the iodixanol gra-
dient peak fractions 11–15, were compared to each other
and to 2% aliquots of the non-purified collection media.
At 1 dpi there was no significant difference in the protein
pattern between the material in non-purified collection
media from HHV-6A- and mock-infected cells (Fig. 3, lane
1 and 2). All detected proteins, e.g. 44 and 88 kD, were
regarded to be cellular proteins.
Infections of JJHAN cells with HHV-6A (U1102) Figure 1
Infections of JJHAN cells with HHV-6A (U1102). A. 
Quantifications of cellular (diamonds) and extracellular 
(squares) HHV-6A DNA. The log10 of the viral DNA copy 
number per ml medium or per 106cells as normalized to 
actin, in inoculum, after 3 hpi and 1, 3, 5 and 7 dpi are shown. 
Results are based on three experiments and presented as 
mean ± standard deviation (error bars). B and C. Light 
microscopic analyses of HHV-6A- and mock-infected JJHAN 
cells at 3 dpi. Note the CPE, i.e. enlargement of cells, in 
HHV-6A infected cells. D and E. Detection of HHV-6 antigen 
gp60/110 in HHV-6A infected cells. HHV-6A-and mock-
infected cells were fixed and stained for gp60/110 (red) and 
counterstained with DAPI (blue) to reveal cell nuclei. Light 
microscopy pictures are magnified 20× and fluorescent pic-
tures 40×.
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Purification of HHV-6A Figure 2
Purification of HHV-6A. A and B. Material in pooled iodixanol gradient fractions were concentrated by centrifugation, sep-
arated by 6–15% SDS-PAGE and visualized by silver nitrate staining or western blot using the viral specific (gp60/110) antibody. 
C. DNA analyses of iodixanol gradient fractions. The number of viral DNA copies in iodixanol gradient fractions of two inde-
pendent experiments was measured by TaqMan based real-time PCR and the densities of the fractions by refractometer. D. 
The proteins in gradient purified material of HHV-6A- and mock-infected cultures were compared by SDS-PAGE stained with 
silver nitrate. Fresh culture medium was analyzed as a control. Estimated molecular weights in kD of the detected proteins are 
indicated. All samples in each separate analysis were equalized to each other based on sample volume. H, M and Mw indicate 
HHV-6A, mock and molecular weight marker.
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In contrast to at 1 dpi, there is a significant difference in
the overall protein pattern between the non-purified col-
lection media samples from HHV-6A-infected cells and
the corresponding mock samples at 3 dpi (Fig. 3, lanes 3
and 6). The HHV-6A samples contain a number of
strongly labelled proteins, which are not present in the
mock sample. This difference is even more pronounced in
the purified material in gradient fractions 11–15 (Fig. 3,
lanes 4 and 5). Since these proteins had no equivalents in
the 1 dpi collection media or in the 3 dpi mock samples
we assumed that they likely are proteins of the viral parti-
cles. Examples are proteins of 220 kD, 158 kD, 106 kD,
76/72 kD, 50 kD and 36 kD. Notable is that the protein
pattern of the metabolically labelled and purified HHV-
6A virions (Fig. 3, lane 4) was very similar to the pattern
found in silver stain analyses of HHV-6A virions (Fig. 2D).
Purification and recovery factors have previously been
estimated by quantifications of metabolically labelled
viral and cellular proteins in the starting material and final
preparation [20-22]. To estimate these factors for the pro-
duced and purified HHV-6A virions at 3 dpi, the pre-
sumed viral proteins, 220, 158 and 50 kD were chosen
and their amounts compared to the 44 and 88 kD cellular
proteins. The measured intensities of the protein bands
were adjusted according to loaded amounts on the gel, i.e.
the 1 dpi and 3 dpi media samples were multiplied 50
times. For calculations of the purification factor, we first
calculated ratios of the viral proteins compared to the 88
kD and 44 kD cellular proteins in 3 dpi medium and in
purified particles in fractions 11–15 of the iodixanol gra-
dient, respectively. A subsequent division of the viral to
cellular protein ratio found in fractions 11–15 with the
corresponding protein ratio in the 3 dpi medium, resulted
in an enrichment factor between 7–15 fold (Table 1). The
recovery was calculated by dividing the intensity of the
individual viral proteins in fractions 11–15 with the
intensity of the proteins in the 3 dpi medium. We found
that the recovery of the viral proteins was about 5% (Table
1). This corresponds well with recovery rates (3.1 ± 1.5%,
n = 4) calculated from real-time PCR analyses of viral
DNA throughout the purification scheme.
Electron microscopy analyses
To further analyze the production and purity of the HHV-
6A particles, EM-analyses were performed. Shown in Fig.
4A is an HHV-6A-infected cell with a number of nucleo-
capsids dispersed in the nucleus (thin arrows) and a com-
plete viral particle located extracellularly (thick arrow).
About 70 of 100 counted cells contained viral particles at
3 dpi. To analyse the cellular material in iodixanol gradi-
ent fractions we pooled fractions 11–15, concentrated the
samples by centrifugation, embedded the pellets in gela-
tine and performed EM-analyses. The analyses of the gra-
dient peak fractions 11–15 showed apparently intact and
spherical virus particles in the HHV-6A sample. Impor-
tantly, no obvious cellular material was visible in the peak
fractions of HHV-6A or in the corresponding mock sam-
ple (Fig. 4B and 4C). The integrity of the purified virions
was further verified by negative staining (data not shown).
We conclude that purification in iodixanol gradients effi-
ciently removes cellular contamination in form of vesicles
and preserves the morphology of the virions.
Purified HHV-6A particles are infectious
To investigate whether the purified virions were infec-
tious, we performed a re-infection assay (Fig. 5). Viral par-
ticles were collected and an aliquot of the non-purified 3
dpi collection medium was used as inoculum for infec-
tion of cells. The remaining collection medium went
through the purification assay and the viral particles in
gradient fraction 11–15 were then used as a second inoc-
Metabolic labelling of proteins in HHV-6A Figure 3
Metabolic labelling of proteins in HHV-6A. HHV-6A- 
or mock-infected cells were metabolically labelled with 
[35S]methionine between 24.5 and 28.5 hpi or 72.5 and 76.5 
hpi and virions were collected without further labelling from 
28.5 to 32.5 hpi or 76.5 to 80.5 hpi. HHV-6A virions and cor-
responding mock sample were purified, equalized based on 
the number of living cells in the two cultures at the end of 
collection period and analyzed by 6–15% SDS-PAGE. The 1 
and 3 dpi media represented 2% of the total sample volume 
and fractions 11–15 corresponded to 98%. Estimated molec-
ular weights in kD of the detected proteins are indicated. H, 
M and Mw abbreviations as in Fig. 3. Asterisks indicate cellular 
proteins 88 kD and 44 kD.
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ulum. Real-time PCR analysis showed that the non-puri-
fied inocula contained approximately 80 times more viral
DNA copies compared to the purified inocula. Cells were
infected with non-purified collection media and purified
fractions 11–15 directly or in 1:2 and 1:4 dilutions. The
two inocula, 1:2 and 1:4 dilutions of the inocula were
used directly to infect one million cells each. The cells
were lysed at 3 dpi, when the first viral particles are
released from infected cells, and at 7 dpi. Viral DNA was
extracted from the samples and the number of viral DNA
copies per cell was determined. To compare the infection
efficiency of the non-purified and purified virions, we cal-
culated the fold increase of viral DNA copies per cell at 3
dpi and 7 dpi compared to corresponding inocula (Fig. 5).
The results show that both non-purified and purified viri-
ons gave similar fold increase in DNA viral copies/cell at
3 dpi, which suggests that both samples contained infec-
tious particles. The same result was obtained at 7 dpi
when comparing non-diluted inocula (Fig. 5). However, a
lower fold increase in DNA viral copies/cell was noticed in
diluted purified inoculum, especially at 7 dpi. This prob-
ably reflects the 80 times lower initial viral copy number
in purified inoculum and at the 1:4 dilution the number
of virions per cell might have reached a critical low point
for successful infections to occur. Another consequence is
that a lower amount of cells were initially infected
although with same efficiency. Thus, less viral particles
were released at 3 dpi that could contribute to a second
round infection. When we analyzed the viral DNA copy
numbers at 1 dpi, 3 dpi, 5 dpi and 7 dpi, we found that
the growth curves for the non-purified inoculum and its
dilutions reached a plateau after 5 dpi as in Fig. 1, which
suggests that almost all cells in the culture had become
infected (data not shown). In contrary, the growth curves
for the purified virions and its dilutions were still increas-
ing even at 7 dpi and probably a third round of infection
would have been necessary in order to infect all cells in the
culture.
In conclusion, the purified and morphological intact
HHV-6A virions retained full infectivity during the purifi-
cation procedure.
Detection of cellular proteins in purified HHV-6A 
preparations
In an attempt to analyze the protein content of purified
HHV-6A virions, with focus on cellular proteins, we per-
formed western blot analysis on samples balanced to each
other on basis of the number of living cells at the end of
collection. We used a set of antibodies directed towards
cellular proteins, including cytoplasmic, cytoskeletal and
surface proteins. We decided to use only those antibodies
that tested clearly positive in cell lysates, which excluded
the antibodies directed towards for example CD4 and
CD55. However anti-clathrin, -ezrin (also to some extent
cross reactive to radixin and moesin), -Tsg101, -actin and
-CD46 antibodies representing cellular vesicle, cytoskele-
tal, cytoplasmic and surface proteins gave a positive signal
in cell lysates of infected and mock cells (Fig. 6, lanes 1 to
4). Next, we analyzed whether the cellular proteins were
detected in aliquots of the non-purified collection media
at 3 dpi. It was found that all selected proteins were to var-
ious degree detected in media collected from HHV-6A
cells, but only Tsg101 and actin gave significant signals in
comparable mock sample (Fig. 6, lanes 5 and 6). The lat-
ter finding indicates that at least Tsg101 and actin are
present in background material released from cells,
regardless if the cells were infected or not. Finally, we ana-
lyzed whether the proteins were present in gradient puri-
fied material from HHV-6A- and mock-infected cells,
respectively (Fig. 6, lane 7 and 8). The results show that
CD46 is clearly found with purified HHV-6A virions, but
is virtually undetectable in the corresponding mock mate-
rial. This suggests an association of CD46 with HHV-6A.
Clathrin, ezrin and Tsg101 also appear to be concentrated
to higher extent in HHV-6A particles compared to the
equally purified mock sample and thus suggesting associ-
ation of these cellular proteins with purified HHV-6A vir-
ions. This was confirmed by quantifications of at least two
Table 1: Recovery and purity of HHV-6A preparations
Viral protein (kD) Recovery (%)1 Virus to host ratio2 Purification factor3
3 dpi Medium #1115
88 kD 44 kD 88 kD 44 kD 88 kD 44 kD
220 5.4 1.8 0.4 27 4.3 15 11
158 5.2 8.3 2.0 119 19 14 9.5
50 4.1 4.2 1.0 47 7.5 11 7.5
1Recovery calculated as (Int(#11–15) /Int(3 dpiMed × 50)) × 100, where Int is the intensity of the proteins as quantified from metabolically labeled proteins 
(Fig. 4).
2Virus to host ratio was calculated as Intviral protein (#11–15)/Inthostprotein (#11–15) and in similar manner for 3 dpi medium.
3Purification factor was estimated as the viral to host ratio in #11–15 divided by the similar ratio in 3 dpi Med.Virology Journal 2007, 4:101 http://www.virologyj.com/content/4/1/101
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independent experiments yielding about 30 times more of
CD46 in purified HHV-6A sample than in the correspond-
ing mock sample. The numbers for clathrin was 4 times,
for ezrin 13 times and for Tsg101 4 times. Actin was also
detected in the purified HHV-6A virions but only 2 times
more when compared to the corresponding mock sample.
However, due to low level of signal to noise ratios, the
quantifications were only approximate.
Discussion
The goal of this study was to establish a purification
method enabling protein analyses, with focus on associ-
ated cellular proteins, of highly purified, morphology pre-
served and still infectious HHV-6A virions. For these
analyses it is important that the isolated particles are as
free as possible from cellular contaminations. To this end,
we modified a purification method previously shown to
yield highly purified retroviral particles [17,18]. First, to
avoid extensive contaminations, we collected the HHV-6A
particles during a short time interval soon after the infec-
tion. Second, the collected virus particles were sedimented
in iso-osmotic iodixanol gradients which efficiently sepa-
rate soluble proteins, cellular vesicles and viral particles
from each other in contrast to sucrose gradients, which
can lead to viral preparations contaminated by cellular
vesicles [14-16]. Another disadvantage with sucrose gradi-
ents is demonstrated by extensive aggregation of HCMV
Purified HHV-6A is infectious Figure 5
Purified HHV-6A is infectious. Cells were infected with 
non-purified collection media and purified fractions 11–15 
directly or in 1:2 and 1:4 dilutions. The infectivity was meas-
ured as the fold increase of viral DNA copies per cell (nor-
malized to actin) at 3 dpi and 7 dpi compared to the initial 
inocula. The fold increase was calculated by dividing the viral 
DNA copy number per cell with the viral DNA copy num-
bers in corresponding inocula.
1
10
100
1000
10000
100000
1000000
purified non-purified purified non-purified
3 dpi/inoculum 7 dpi/inoculum
1:1   1:2   1:4   1:1   1:2   1:4
F
o
l
d
 
i
n
c
r
e
a
s
e
 
o
f
 
v
i
r
a
l
 
D
N
A
 
c
o
p
i
e
s
 
p
e
r
 
c
e
l
l
1:1   1:2   1:4   1:1   1:2   1:4
EM thin section analyses of infected cells and of particles in  iodixanol gradient fractions Figure 4
EM thin section analyses of infected cells and of parti-
cles in iodixanol gradient fractions. A. HHV-6A infected 
cells at 3 dpi. Indicated are viral nucleocapsids (thin arrows) 
in cell nuclei and virions released into the extracellular milieu 
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rial in gradient fractions 11–15. Note the intact and morpho-
logically preserved HHV-6A particles in material from HHV-
6A-infected cells (B) and their absence in samples from 
mock-infected cells (C). The bars are 500 nm.
Nu
Cy
A
B
Gelatine
B
Gelatine
B Gelatine CVirology Journal 2007, 4:101 http://www.virologyj.com/content/4/1/101
Page 8 of 11
(page number not for citation purposes)
particles during sedimentation, which may influence the
infectivity of the purified virus [23,24]. Third and most
importantly, controls for release of cellular material and
contamination of purified preparations were included.
For this purpose we analyzed material released from com-
parable mock-infected cells and fresh culture media.
The efficiency of purification was followed by thin section
EM analyses to investigate the overall content of the viral
preparations [22]. The result showed that the viral prepa-
rations were purified from contaminations in form of
large aggregates or cellular vesicles. Besides, the viral par-
ticles had intact morphology since no stain penetrated the
particles in negative stain analyses. Despite efficient puri-
fication, the virions were to some extent contaminated by
serum proteins as seen in sensitive silver stain analyses
[25]. We made an effort to further reduce the level of
serum contamination by slowly reducing the level of
serum in cell culture to only 0.2%. However, the produc-
tion of virus particles was decreased and the method was
therefore abandoned. It should be noted, that HCMV
[26], Epstein-Barr virus (EBV) [27] and Human herpesvi-
rus 8 (HHV-8) [28] can be purified to levels where serum
bands are not detected by the 100 times less sensitive
Coomassie Brilliant blue staining [25]. However, compa-
rable control samples have seldom been shown, which
makes the purity difficult to estimate. Purifications of
HHV-6B have often included time consuming sedimenta-
tions in cesium chloride gradients [29,30]. Notable is also
that purification protocols for other viruses have given
higher purification folds and recovery rates than those we
obtained. We have, on the other hand, aimed to reduce
the contamination already by short collection times at a
suitable time point. Previous purification protocols have
often not assessed the infectivity capacity of the final
product. We demonstrate that HHV-6A particles purified
in iodixanol gradients are infectious. Our assay might be
an alternative method, if fast and mild one-day purifica-
tion of viable viral particles is required.
The HHV-6A viral preparations were to low extent con-
taminated by cellular proteins as seen in metabolic label-
ling experiments. However, the cells were sensitive to the
toxic effects of the isotope, which was manifested in
increased background with prolonged labelling times.
Hence, the protein background found in purified prepara-
tions during metabolic labelling might not be fully repre-
sentative of the protein contamination level of non-
labelled HHV-6A preparations. It should be noted that the
background level of metabolically labelled material in
these analyses could be influenced by three parameters.
First, increase of cell number in the mock culture com-
pared to the HHV-6A-infected culture may result in over-
estimating of released cellular material from mock
culture. Therefore, the analyses were based on the number
of living cells in the cultures at the end of collection of
virus particles. Second, cells are dying during the experi-
ment and material is released into the culture media. The
cells were counted throughout the experiments and the
number of dead cells in HHV-6A- and mock-infected cul-
tures did not differ extensively (data not shown). Also,
that the cells were washed at every step of the experiment
including at the start of labelling and before collection of
particles, which reduce the amount of released soluble
material in the collection media. Third, HHV-6A-infected
cells might react differently from mock-infected cells and
due to the infection release a higher extent of cellular
material or a different set of proteins into the collection
media, which may result in an increase of cellular proteins
in purified virions. However, two representative cellular
proteins, 44 kD and 88 kD, are found at similar levels in
the purified samples of both HHV-6A and mock at both 1
dpi (data not shown) and 3 dpi, indicating that our con-
trol consisting of material released from mock-infected
cells is comparable to the proportion of material released
from HHV-6A-infected cells, Therefore, we conclude that
the cellular proteins CD46, clathrin heavy chain, ezrin,
and Tsg101 are associated with the purified HHV-6A viri-
ons. Actin might also be associated with purified HHV-6A
since it was found at a level of 2 times more than in the
Identification of cellular proteins associated with HHV-6A  particles Figure 6
Identification of cellular proteins associated with 
HHV-6A particles. Media from HHV-6A- and mock-
infected JJHAN cells were collected at 3 dpi and 2% aliquots 
were used directly for SDS-PAGE and western blot analyses 
and compared to the further purified material in iodixanol 
gradient fractions 11–15. The amounts of the mock (M) and 
HHV-6A (H) samples were equalized based on the number 
of living cells in the two cultures at the end of the collection. 
Cell lysates were analyzed in two amounts, 1× = 0.35 × 104 
cells and 10× = 3.5 × 104 cells.
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corresponding mock sample. However, it is doubtful if 2
times more is significant and therefore we just conclude
that actin was present in the purified HHV-6A sample.
CD46 is the receptor for HHV-6A [31] and as such it can
be discussed whether soluble or vesicle bound CD46
released from the infected cells might bind to the pro-
duced HHV-6A virions and account for the high associa-
tion of CD46 with purified HHV-6A virions. However, the
issue of unspecific attachment of released proteins to pro-
duced virions has been examined before and found to not
significantly contribute to the number of associated pro-
teins [17]. Association of CD46 with HHV-6A viral parti-
cles has previously been indirectly shown in MS patient
samples. In that study, HHV-6A particles from 4 out of 42
MS patient sera were isolated using an immunoaffinity
column comprised of immobilized monoclonal antibody
towards CD46 [32]. Our present results confirm a direct
association of CD46 with HHV-6A virions.
Incorporation of host proteins, like complement proteins,
into viral particles may exert beneficial effects for the virus
as protection from complement mediated lysis
[13,33,34]. However, incorporation of host material may
also result in detrimental immune responses, such as
autoreactive B- and T cells [9,35]. For instance, addition of
myelin basic protein to the enveloped virus VV was shown
to be important for autoimmunity and induction of
encephalomyelitis [36]. Given that HHV-6A forms a
latent infection in the brain [37] and that reactivation of
the virus has been detected in oligodendrocytes in MS
patients [7], it is of high relevance to investigate the over-
all protein content of any HHV-6A particles and especially
in those released from human oligodendrocytes and to
analyze the subsequent immunological events. However,
such a study is impeded due to difficulties in obtaining
and propagating sufficient amount of human oli-
godendrocytes. Our present study is a first attempt to
investigate these issues and the results show that a
number of diverse cellular proteins are associated with
purified HHV-6A particles produced in JJHAN cells. This
opens up for the possible incorporation of other cellular
proteins, such as myelin in HHV-6A particles produced in
oligodendrocytes, and further investigations of mecha-
nisms for induction of autoimmune reactions.
Conclusion
HHV-6A virions were purified using iodixanol gradient,
which efficiently separate cellular vesicles and virions. The
purification yielded morphology intact and infectious
particles. Purity was assessed in each step of the purifica-
tion procedure by comparing with a control consisting of
material released from mock-infected cells. CD46, clath-
rin, ezrin and Tsg101 were found to be several times more
concentrated in the purified virus sample than in the sim-
ilarly purified sample from mock infected cells. This sug-
gests that these cellular proteins are specifically associated
with the virions.  
Methods
Viruses and cell lines
HHV-6A (U1102) was propagated in the Human T-cell
lymphoblastoid cell line JJHAN as previously described
[38].
HHV-6A infection
JJHAN cells were washed with phosphate buffered saline
(PBS) and infected with clarified inocula containing
about 1.3 × 108 DNA viral copies of HHV-6A (U1102) per
106 cells. After 3 h incubation, cells were washed and
maintained in RPMI containing 10% FCS for 24 h. The
cells were washed and RPMI containing 2% FCS was
added and incubation continued. At time points 3 h, 1, 3,
5 and 7 days post infection (dpi), cells and media were
harvested for DNA extraction. Samples for immunofluo-
rescence assay and electron microscopy were taken at 3
dpi. Mock infection was carried out using clarified culture
media of uninfected JJHAN cells.
Production, isolation and purification of viral particles
HHV-6 particles and mock material were collected in
RPMI containing 2% FCS media at chosen time intervals,
mostly 1 dpi to 3 dpi. Media was clarified by centrifuga-
tions twice for 10 min at 2000 × g in a Heraeus Labofuge
400R centrifuge and once for 20 min at 39 813 × g and
10°C in a Beckman JA17 rotor and then concentrated by
ultra filtration in Millipore Amicon Ultra-15 tubes (Milli-
pore Corporation, Bedford MA, USA) at 3939 × g  for
repeated 10 min intervals at 20°C in a Heraeus Labofuge
400R centrifuge until about 1 ml remained. The concen-
trated media were filtered through a Millipore low protein
binding Durapore 0.45 µm filter (Millipore Corporation,
Bedford MA, USA), layered on top of a 5 to 25% (w/v)
iodixanol gradient (Axis-Shield PoC AS, Oslo, Norway)
and particles were purified by sedimentation for 1.5 h at
160 000 × g at 4°C in a Beckman SW41 rotor. The gradi-
ents were fractionated from the top (700 µl/fraction) and
virus containing fractions were detected by real time PCR,
pooled, diluted by TNE (50 mM Tris-HCl pH 7.4, 100 mM
NaCl, 0.5 mM EDTA) and concentrated by centrifugation
in a Beckman SW41 rotor at 151 260 × g at 4°C for 1.5 h.
Alternatively, individual gradient fractions were diluted in
TNE and concentrated by centrifugation at 34 000 × at
10°C for 1.5 h in a Beckman JA18.1 rotor.
The refractive index (Ri) of the gradient fractions were
measured and their densities (δ) calculated by the formula
δ = 3.362 × Ri-3.483.
Cells were lysed in 1% Nonidet P-40, 50 mM Tris-HCl pH
7.6, 150 mM NaCl, 2 mM EDTA, 1 µg/ml phenyl methylVirology Journal 2007, 4:101 http://www.virologyj.com/content/4/1/101
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sulfonyl fluoride on ice and the lysate was clarified by a 5
min 6000 rpm (3709 × g) centrifugation in a table top
Eppendorf centrifuge.
DNA extraction and quantitative real-time TaqMan PCR
Extraction of DNA and determination of viral DNA copies
for HHV-6A was performed as previously described [38].
The viral DNA copy number (NHHV-6A) per one million
cells was calculated by the following formula: (NHHV-6A) ×
(Nβ-actin
-1) × 0.5 × 106. Final number of viral DNA copies
in collected culture media was expressed as viral DNA
copies/ml.
Analysis by SDS-PAGE and silver staining
Samples were separated on SDS 6–15% gradient polyacr-
ylamide gel electrophoresis (PAGE) as described [17]. The
samples were normalized to each other by volumes of the
samples or by the number of living cells from which the
samples were produced. Silver stain was performed essen-
tially as described [39]. The gel was fixed in 40% (v/v) eth-
anol and 10% (v/v) acetic acid for 1 h, washed with water
for 15 min, incubated twice for 30 min with 0.05% (w/v)
2-,7-napfthalenedisulfonic acid disodium salt, washed
with water four times for 15 min and incubated for 30
min in a 0.8% (w/v) AgNO3, 0.34% (v/v) NH3 and 18 mM
NaOH mixture. The gel was washed with water, developed
with 0.01% (w/v) citric acid, 0.01% (v/v) formaldehyde
mixture and the reaction was stopped with 5% (v/v) acetic
acid. The gel was washed with water, dried and scanned by
a CanoScan 8400F (Canon Svenska AB, Solna, Sweden).
Western blot analyses
The primary antibodies used were anti-gp60/110
(MAB8537) and anti-actin (MAB1501-R) (Chemicon
International, Temecula, CA, USA), the anti-Tsg101 (sc-
6037), anti-ezrin (sc-6407), anti-clathrin HC (sc-6579)
and anti-CD46 (sc-9098) (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA). The secondary antibodies used
were horseradish peroxidase conjugated donkey anti-rab-
bit IgG (NA934), sheep anti-mouse IgG (NA931) (Amer-
sham Pharmacia Biotech, Uppsala, Sweden) and donkey
anti-goat IgG (sc-2020, Santa Cruz Biotechnology). West-
ern blot were performed as described [17]. Quantifica-
tions of detected proteins were performed by using a Versa
Doc Imaging system, model 4000 and the QuantityOne
program from Bio-Rad Laboratories (Hercules, CA, USA).
Indirect Immunofluorescent Assay
Fluorescence microscopy analysis for gp60/110 was con-
ducted as previously described [38].
Transmission Electron Microscopy
Negative staining of virions in gradient fractions and prep-
aration of JJHAN cells was done as described [38,40].
Material in iodixanol gradient fractions 11–15 were con-
centrated by centrifugation and the pellets were embed-
ded in a droplet of warm 10% gelatine in PBS (37°C) for
10 min. The samples were fixed, postfixed, sectioned and
stained [38]. Sections were examined in a Tecnai 10 (Fei
Company, Eindhoven, The Netherlands) microscope
operated at 80 kV equipped with a MegaView 3 digital
camera. The images were acquired and analyzed with the
image processing software Analysis (Soft Imaging system
GmbH, Munster, Germany).
Metabolic labelling
The cells were infected for 3 h and maintained in RPMI
containing 5% FCS for 21 or 69 h. The cells were washed
with PBS and incubated for 30 min in low-methionine
DMEM medium (3.0 µg of methionine/ml) (medium no.
991303; National Veterinary Institute, Uppsala, Sweden)
supplemented with phosphate up to the regular concen-
tration of 125 µg/ml, 2 mM glutamine, 5% FCS, 20 mM
HEPES, 100 U of penicillin/ml and 100 µg of streptomy-
cin/ml. The cells were labelled for 4 h in fresh similar
media supplemented with 100 µCi/ml of [35S]methio-
nine. The cells were washed with PBS, RPMI containing
2% FCS supplemented with an excess of unlabeled
methionine (300 µg/ml) was added and virus collected
from 28.5 to 32.5 or 76.5 to 80.5 hpi. The particles were
collected, purified and analysed by SDS-PAGE. The gel
was fixed in 10% trichloroacetic acid-40% methanol for
30 min at RT before being dried and exposed to a BAS-
MS2025 image plate from Fujifilm (Science Imaging Scan-
dinavia, Nacka, Sweden). The amount of radioactivity in
proteins was measured using a Molecular Imager FX, and
the QuantityOne program from Bio-Rad Laboratories
(Hercules, CA, USA).
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